COMP <GO>
PDEX vs JNJ // RSI-14 & 200D SMA MOMENTUM
Pro-Dex Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: PDEX 4
— JNJ 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: JNJ
LAST: $61.60 (-2.52%) • MKT CAP: $199.2M
rsi-technicals
47.7
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
rsi-technicals
62.1
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PDEX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PDEX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 29.30% | 67.90% | -38.60 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 23.20% | 25.50% | -2.30 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.5x | 18.5x | -2.00 | PDEX | /valuation <GO> |
| Free Cash Flow Yield | -1.47% | 2.97% | -4.44 | JNJ | /fcf-yield <GO> |
| Operating Margin | 16.10% | 34.70% | -18.60 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 13.50% | 28.50% | -15.00 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 23.70% | 6.00% | +17.70 | PDEX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.08 | 5.59 | +3.49 | PDEX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 47.7 | 62.1 | -14.40 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.6x | 23.0x | -4.40 | PDEX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $199.2M | $662.49B | -$662.29B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PDEX REV | JNJ REV | PDEX GROSS % | JNJ GROSS % | PDEX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $66.6M | $94.19B | 29.3% | 67.9% | -$2.9M | $19.70B |
| FY 2024 | $53.8M | $88.82B | 27.0% | 69.1% | $6.2M | $19.84B |
| FY 2023 | $46.1M | $85.16B | — | — | $5.5M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PDEX // BETA —
JNJ // BETA 1.08